Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
News for Vicarious Surgical Inc. (RBOT) centers on its progress in developing the Vicarious Surgical Robotic System and on key corporate and financing events. The company describes itself as a next-generation surgical robotics and medical device developer focused on minimally invasive surgery, with a system designed for abdominal access and 3D visualization through a single port.
Recent press releases highlight development milestones such as an in-vivo porcine lab in which surgeons used the company’s pre-DV system to complete key elements of a ventral hernia repair and evaluate subsystems including instrument articulation, energy delivery instruments and visualization. These updates provide insight into how the system performs in realistic surgical environments and how data from such labs inform design refinement, verification planning and system optimization.
Investors and observers will also find news about Vicarious Surgical’s operating model and cost structure. The company has issued cash burn guidance, discussed an operational reset, and announced reductions in headcount and external consulting spend, alongside increased use of strategic outsourcing and a strategic software execution partnership with a global digital engineering firm. These items describe how Vicarious Surgical is seeking to improve execution, increase development predictability and manage operating expenses while advancing toward system design milestones.
Additional news coverage includes quarterly financial results, registered direct offerings and private placements, at-the-market offering arrangements, board and committee changes, and participation in healthcare investment conferences. Together, these updates give a view into both the technical evolution of the Vicarious Surgical System and the company’s financing, governance and investor relations activities. Readers interested in RBOT can use this page to follow ongoing disclosures about development progress, financial guidance, capital raises and corporate governance developments.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, scheduled for August 31, 2022, at 11:30 am ET. The virtual event aims to highlight emerging growth companies. Vicarious Surgical focuses on enhancing surgical efficiency and patient outcomes through advanced robotic technology. A live webcast will be available through a provided link, with an archived version accessible on their investor website following the event.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its Q2 2022 financial results, revealing a significant increase in operating expenses to $19.1 million, up from $6.6 million in Q2 2021. Adjusted net loss rose to $19.1 million, or $0.16 per share, compared to a loss of $6.6 million or $0.08 per share in the previous year. The company is advancing its Beta 2 system and partnering with UH Ventures and HCA Healthcare for surgical innovations. Cash burn rate for the quarter was $15.7 million. A conference call will be held today at 4:30 p.m. ET.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) has announced its participation in the Canaccord Genuity 42nd Annual Growth Conference set for Wednesday, August 10 at 9:30 a.m. ET. A live webcast of the presentation will be available on the company’s website, with an archive for later viewing. Founded in 2014 and headquartered in Waltham, Massachusetts, Vicarious Surgical is pioneering robotic technology aimed at enhancing surgical efficiency and patient outcomes while reducing healthcare costs.
Vicarious Surgical Inc. (NYSE: RBOT) will report its second quarter 2022 financial results on August 8, 2022, after market close. A conference call, open to investors, will begin at 4:30 p.m. Eastern Time. The company, founded in 2014, focuses on developing advanced robotics for minimally invasive surgery, aiming to enhance efficiency and reduce healthcare costs. Vicarious Surgical is backed by notable investors, including Bill Gates and Vinod Khosla, and is headquartered in Waltham, Massachusetts.
Vicarious Surgical has entered into Center of Excellence agreements with HCA Healthcare and University Hospitals Ventures. These partnerships aim to enhance the design and commercialization of the Company's robotic surgical system, incorporating real-world feedback from surgeons and healthcare administrators. This collaboration provides Vicarious Surgical with critical insights into surgical workflows, promoting the system's readiness for FDA approval. The partnerships are viewed as significant validation of its in-hospital potential, positioning Vicarious Surgical for future growth in the competitive healthcare market.
Vicarious Surgical Inc. (NYSE: RBOT) will be added to the Russell 3000®, Russell 2000®, and Russell Microcap® Indexes following the annual reconstitution on June 27, 2022. This inclusion recognizes the company as one of the 4,000 largest U.S. stocks based on market capitalization. CEO Adam Sachs expressed that this milestone will enhance institutional visibility and engagement. Russell indexes, which are benchmarks for approximately $12 trillion in assets, offer a significant platform for investors.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in the Cowen 7th Annual FutureHealth Conference. Management will present on June 22 at 10:50 a.m. ET, and a live webcast will be accessible on the company’s website. Founded in 2014 and headquartered in Waltham, Massachusetts, Vicarious Surgical develops advanced robotics technology aimed at improving patient outcomes and reducing healthcare costs through minimally invasive surgeries.
Vicarious Surgical announced its financial results for Q1 2022, reporting a substantial increase in operating expenses to $18.2 million from $5.2 million in Q1 2021, marking a 248% rise. R&D costs rose to $9.8 million, while general and administrative expenses reached $6.9 million. The adjusted net loss was $18.2 million, or $0.15 per share, compared to a loss of $5.2 million, or $0.06 per share, in the previous year. Notably, GAAP net income was $42.5 million, translating to net income per share of $0.35. The company continues to advance its Vicarious System with successful beta testing.
Vicarious Surgical Inc. (NYSE: RBOT) announced it will report financial results for Q1 2022 after market close on May 9, 2022. Management will host a conference call at 4:30 p.m. Eastern Time. Investors can participate by calling +1 (646) 904 5544 for domestic or +1 (929) 526 1599 for international access using code: 646287. The company focuses on enhancing surgical procedures' efficiency and outcomes using proprietary robotic technology. Founded in 2014 and based in Waltham, Massachusetts, Vicarious Surgical is backed by notable investors including Bill Gates.
Vicarious Surgical, Inc. (NYSE:RBOT) has successfully qualified its cleanroom for manufacturing the Vicarious System, enhancing its capabilities for precision assembly. This qualification ensures adherence to stringent efficiency and quality standards, marking a significant step towards market readiness. The Vicarious System aims to improve surgical outcomes by facilitating procedures through a single port, promoting faster patient recovery. CEO Adam Sachs emphasized the importance of a quality-controlled manufacturing process in achieving better healthcare outcomes.